Patents Assigned to Diabact AB
  • Publication number: 20070031502
    Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
    Type: Application
    Filed: October 10, 2006
    Publication date: February 8, 2007
    Applicant: DIABACT AB
    Inventors: Anders Pettersson, Christer Nystrom
  • Publication number: 20040213855
    Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
    Type: Application
    Filed: May 24, 2004
    Publication date: October 28, 2004
    Applicant: DIABACT AB
    Inventors: Anders Pettersson, Christer Nystrom
  • Patent number: 6761910
    Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 13, 2004
    Assignee: Diabact AB
    Inventors: Anders Pettersson, Christer Nystrom
  • Patent number: 6759059
    Abstract: A pharmaceutical composition for the treatment of acute pain by sublingual administration is described. The composition comprises an essentially water-free, ordered mixture of fentanyl or a pharmaceutically acceptable salt thereof in the form of microparticles which are adhered to the surface of carrier particles which are substantially larger than the particles of fentanyl, and are essentially water-soluble. In a preferred embodiment, the composition also contains a bioadhesion and/or mucoadhesion promoting agent. The invention also relates to the preparation of the composition, and to the use of the composition for the treatment of acute pain.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 6, 2004
    Assignee: Diabact AB
    Inventors: Anders Pettersson, Christer Nystrom, Hans Lennernas, Bo Lennernas, Thomas Hedner
  • Patent number: 6113875
    Abstract: A preparation for administering isotope-labelled urea together with acid in a solid form that is influenced by activity of Helicobacter pylori in the stomach only, avoiding any non-Helicobacter (unspecific) urease activity in the oral cavity and the pharynx. The preparation dissolves very quickly in the stomach. The preparation is used to show increased urease activity in the stomach in association with an ongoing Helicobacter pylori infection.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: September 5, 2000
    Assignee: Diabact AB
    Inventors: Christer Nystrom, Thomas Lundqvist, Anders Pettersson
  • Patent number: 6083756
    Abstract: A method for identification of an infant being particularly susceptible to sudden infant death syndrome (SIDS) comprises the determination of an Helicobacter pylori infection in the infant's mother, particularly by detection of antibodies to H. pylori of the IgG type, in a blood sample drawn from the infant's mother or by determination of carbon dioxide formed from urea in the air exhaled from the infant's mother upon oral administration of a challenge dose of urea. Also disclosed is the use of an antibiotic effective against H. pylori for the manufacture of a medicament for administration to mothers and other persons infected by H. pylori and coming into close bodily contact with infants below two years of age, and a method of prevention of SIDS by administration of that antibiotic.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: July 4, 2000
    Assignee: Diabact AB
    Inventors: Jan Hedner, Anders Pettersson